Pancreatic Cancer Research

ResearcherVýchodoslovenský ústav srdcových a cievnych chorôb, a.s.Active in the last 2 years

Matúš Čoma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4450-2083; OpenAlex author ID A5067010396. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

  1. Tigecycline Enhances Sensitivity to FOLFIRINOX and Gemcitabine/Nab-Paclitaxel in Pancreatic Ductal Adenocarcinoma In Vitro Models Last author DOI 10.1007/s44411-026-00676-1↗
  2. Desmoplastic Crosstalk in Pancreatic Ductal Adenocarcinoma Is Reflected by Different Responses of Panc-1, MIAPaCa-2, PaTu-8902, and CAPAN-2 Cell Lines to Cance… Co-author DOI 10.21873/cgp.20254↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jana Sabová · 1 shared paper, 2026 · strength 0.39
  2. R Gürlich · 1 shared paper, 2021 · strength 0.10
  3. Stepan Novak · 1 shared paper, 2021 · strength 0.10
  4. Árpád Szabó · 1 shared paper, 2021 · strength 0.10
  5. Pavol Szabó · 1 shared paper, 2021 · strength 0.10
  6. Josef Dvořák · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.